Understanding why some melanoma patients don't respond to immunotherapy
Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies
This study is looking at why some melanoma patients don’t respond to immunotherapy and aims to find clues in their biopsies that could help doctors predict who will benefit from these treatments, so your participation could help improve future care for melanoma.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11093978 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind resistance to immunotherapies in melanoma patients. By analyzing pre-treatment biopsies and clinical data, the team aims to identify biomarkers that can predict which patients will benefit from specific immunotherapy treatments. The study includes both preclinical and clinical components, utilizing advanced proteogenomic techniques to refine existing response signatures and understand immune-related adverse events. Patients participating in this research may contribute to the development of more effective treatment strategies for melanoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are melanoma patients who are considering or currently undergoing immunotherapy treatments.
Not a fit: Patients with melanoma who are not eligible for immunotherapy or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and better patient outcomes for those with melanoma.
How similar studies have performed: Previous research has shown promise in understanding immunotherapy responses, but this study aims to explore novel mechanisms and biomarkers that have not been extensively tested.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Paulovich, Amanda G — Fred Hutchinson Cancer Center
- Study coordinator: Paulovich, Amanda G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.